Lexicon Pharmaceuticals, Inc. (LXRX)
| Previous Close | 1.6200 |
| Open | 1.6700 |
| Bid | 1.6500 x 1000 |
| Ask | 1.6700 x 200 |
| Day's Range | 1.6250 - 1.7000 |
| 52 Week Range | 0.9200 - 3.7900 |
| Volume | |
| Avg. Volume | 4,856,090 |
| Market Cap | 409.985M |
| Beta (5Y Monthly) | 1.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8000 |
| Earnings Date | Apr 30, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
GlobeNewswireLexicon Pharmaceuticals to Host 2024 Investor Day
Includes Business and Scientific Updates from Lexicon Executives and Leading Medical Experts in Hypertrophic Cardiomyopathy, Type 1 Diabetes and Diabetic Peripheral Neuropathic PainTHE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the Lexicon 2024 Investor Day on April 22, 2024. The event will be held in New York City from 9:00 a.m. to 12:00 p.m. ET. Business
ZacksAll You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
Lexicon (LXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GlobeNewswire
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in a moderated discussion at the 23rd Annual Needham Virtual Healthcare conference Wednesday April 10th, 1:30-2:10pm. A simultaneous webca
